TFO
TSHA icon

Tarbox Family Office’s Taysha Gene Therapies TSHA Stock Holding History

Tarbox Family Office’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-175
Closed -$1K – 906
2022
Q1 		$1K Buy
+175
New +$1.31K ﹤0.01% 1020

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Tarbox Family Office's TSHA Position: Q2 2022 in Review

Tarbox Family Office sold out of Taysha Gene Therapies (TSHA) in Q2 2022, closing a stake of 175 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in TSHA in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 59 funds tracked by Wall St. Rank hold TSHA as of Q2 2022.

  • Tarbox Family Office reported no remaining Taysha Gene Therapies position as of Q2 2022 after selling out during the quarter.
  • Tarbox Family Office sold 175 Taysha Gene Therapies shares in Q2 2022, an estimated $1K.
  • Tarbox Family Office first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 1 quarter.
  • Tarbox Family Office's Taysha Gene Therapies position peaked at $1K in Q1 2022.
  • 59 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2022.

Based on Tarbox Family Office's 13F filing for Q2 2022, filed 19 Jul 2022.